Global Market for Hormonal Contraceptives and Infertility Drugs, 2005-2012; The

Publication Date	January 2006
Publisher	Spectra Intelligence
Product Type	Report
Pages	109
ISBN Number	not applicable
Product Code	SPE00007

Price

£1,900.00
approximately: $3,550 | €2,410

CD-ROM £1,900 ($3,550 | €2,410)

Order above formats by FAX

Summary

Drugs in reproductive medicine are evolving into highly sophisticated products with multifunctional pharmacological properties and clinical utilities. for example, novel contraceptive formulations with low side-effect profiles are increasingly being introduced to provide women with flexible birth-control and menstrual management options whilst also offering secondary indications to treat coexisting endocrinological and gynaecological disorders. Additionally, the increasing global prevalence of infertility is driving R&D to offer novel drug solutions to improve or restore male- and female-factor infertility, optimize fertilization and embryo implantation, and reduce miscarriage.

Recent advances in administering and formulating hormone-based drugs is enabling a revolution in contraception and infertility treatments. over the next decade, the market for hormonal contraceptives and infertility drugs is predicted to expand considerably through innovation, new and expanding markets, and high-value prospects that importantly offer novel solutions to unmet needs and demands of patients who wish to modulate or enhance fertility. The current mature market for hormonal contraceptives and infertility drugs is estimated at US$7.1 billion in 2006 but is forecast to increase 40% to US$9.9 billion by 2012.

in this report, The Global Market for Hormonal Contraceptives and Infertility Drugs, 2005-2012, the reader will be introduced to an analysis of current and prospective markets, drug research and development, and company activities within the hormonal contraception and infertility therapy sectors. The report illustrates how pharmacological innovation is revolutionizing treatments to control fertility for both men and women and provides a detailed account of the new prospects that are anticipated to expand the market substantially over the next decade. Novel research and drug development areas such as male contraception and spermatogenesis induction are discussed in relation to unmet needs illustrating new trends in R&D, and the potential for high returns on investment in poorly served market segments.

The report provides a detailed analysis of the sector to include insights for product extension and reformulation, sales forecasts to 2012, and impact of late-stage pipeline drugs on the market. An overview of R&D programs within the field is also highlighted showing products from preclinical to premarket authorization phases of development, with promising agents further discussed from commercial and drug development perspectives.

Therapy area forecasting and illustrative market data and analysis is also presented to offer insights into potential top-performing products; therapy forecasting to 2020 also enables the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.

Objectives of The Report

The objectives of this report are to provide an in-depth analysis of the global therapeutic market for hormonal contraceptives and infertility drugs. Included in this study are analyses of key therapy areas, R&D programs, and innovating companies and products. IT is hoped that the reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.

Content

Executive Summary
Objectives of the Report
Research Methodology
Chapter 1 Introduction to Reproductive Medicine
- Ageing, Lifestyle Issues, and Reproductive Health
- Elective Infertility - Contraception
- The Birth of Contraception
- Inducing Infertility via Ovulation Suppression
- Combined Oral Contraceptives
- Fertility Disorders
- Assisted Conception
Chapter 2 Hormonal Contraceptives and Infertility Drug Markets 21
- Reproductive Medicine Market Overview
- Market Analysis: Contraception and Infertility
- Hormonal Contraception
- Contraceptive Formulations
- Combined Oestrogen-Progestogen Contraceptives
- Progestogen-Only Contraceptives
- Product Market for Hormonal Contraceptives
- Janssen-Cilag/Ortho-McNeil/Johnson & Johnson
- Key Product and Portfolio Review
- Sales Estimates and Product Market Outlook
- Organon/Akzo Nobel
- Key Product and Portfolio Review
- Pipeline Focus
- EMM 310066
- Male Contraception - Organon/Schering
- Sales Estimates and Product Market Outlook
- Pharmacia/Pfizer
- Key Product and Portfolio Review
- Sales Estimates and Product Market Outlook
- Schering/Berlex
- Key Product and Portfolio Review
- Pipeline Focus
- Yaz
- Contraceptive Patch
- E2/DNG Pill
- Male Contraception
- Sales Estimates and Product Market Outlook
- Wyeth
- Key Product and Portfolio Review
- Sales Estimates and Product Market Outlook
- Barr Laboratories
- Key Product and Portfolio Review
- Pipeline Focus
- Sales Estimates and Product Market Outlook
- Promising Contraceptives in Research and Development
- Male Contraception
- University of Washington/National Institute of Child Health and Human Development, USA
- Miglustat
- Nestorone Gel
- Future Considerations and Outlook for the Contraceptive Product Market
- Infertility Pharmacotherapeutics
- Pharmacotherapies for Infertility
- Mechanism of Action of Infertility Pharmacotherapeutics
- Product Market Analysis for Infertility Pharmacotherapeutics
- AstraZeneca
- Key Product and Portfolio Review
- Sales Estimates and Product Market Outlook
- Ferring
- Key Product and Portfolio Review
- Pipeline Focus
- Sales Estimates and Product Market Outlook
- Organon
- Key Product and Portfolio Review
- Pipeline Focus
- Sales Estimates and Product Market Outlook
- Serono
- Key Product and Portfolio Review
- Pipeline Focus
- Sales Estimates and Product Market Outlook
- Future Considerations and Market Insights for Infertility Pharmacotherapeutics 79
- Promising Infertility Drugs in Research and Development
- Novel Female Infertility Pharmacotherapeutics
- Vitropin - Vitro Diagnostics
- PV903 - GroPep
- Novel Male Infertility Pharmacotherapeutics
- BIO316 - Enhance Biotech/Bioaccelerate
- Menevit - Repromed, University of Adelaide
- Commercial Prospects for Infertility Drugs
Chapter 3 Drugs in Research and Development
- Contraception
- Research and Development Overview
- Infertility
- Research and Development Overview
Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining
- Reproductive Medicine: Contraception and Infertility
- Therapy Area Forecasts
- Market Share of Reproductive Medicine Therapy Areas
- Comparative Analysis: Product Sales 100
- Prospect Mining
- Contraception
- Infertility
- Therapy Area Forecasts: 2012 and 2020
Chapter 5 Report Synopsis
- Contraception - Key Data Points
- Infertility - Key Data Points
- Table 1.1 Global Prevalence Rates of Oral Contraceptive Use
- Table 1.2 Popular Combined Oral Contraceptives, 2005
- Table 1.3 Biological Causes of Infertility
- Table 1.4 Assisted Conception Techniques
- Table 2.1 Estimated Global Sales (US$) & Forecasts of Leading Hormonal Contraceptives and Infertility Drugs, 2004-2012
- Table 2.2 Selection of Contraceptives Segmented by Formulation and Delivery Route
- Table 2.3 Johnson & Johnson's Hormonal Contraceptive Product Portfolio, 2005
- Table 2.4 Estimated Sales (US$) and Annual Growth (%) of Ortho-McNeil/Johnson & Johnson's Hormonal Contraceptive Portfolio, 2005-2012
- Table 2.5 Organon/Akzo Nobel's Hormonal Contraceptive Product Portfolio, 2005
- Table 2.6 Estimated Sales (US$) and Annual Growth (%) of Organon/Akzo Nobel's Hormonal Contraceptive Portfolio, 2005-2012
- Table 2.7 Pfizer's Hormonal Contraceptive Product Portfolio, 2005
- Table 2.8 Estimated Sales (US$) and Annual Growth (%) of Pfizer's Hormonal Contraceptive Portfolio, 2005-2012
- Table 2.9 Schering/Berlex' Hormonal Contraceptive Product Portfolio, 2005
- Table 2.10 Schering/Berlex' Pipeline Contraceptive Candidates, 2005
- Table 2.11 Estimated Sales (US$) and Annual Growth (%) of Schering/Berlex' Hormonal Contraceptive Portfolio, 2005-2012
- Table 2.12 Wyeth's Hormonal Contraceptive Product Portfolio, 2005
- Table 2.13 Estimated Sales (US$) and Annual Growth (%) of Wyeth's Hormonal Contraceptive Portfolio, 2005-2012
- Table 2.14 Barr's Hormonal Contraceptive Product Portfolio, 2005
- Table 2.15 Estimated Sales (US$) and Annual Growth (%) of Barr's Hormonal Contraceptive Portfolio, 2005-2012
- Table 2.16 Pipeline Hormonal Contraceptives, 2005
- Table 2.17 Pharmacotherapies for Infertility, 2005
- Table 2.18 AstraZeneca's Hormonal Infertility Product Portfolio, 2005
- Table 2.19 Estimated Global Sales (US$) and Annual Growth (%) of AstraZeneca's Hormonal Infertility Products, 2005-2012
- Table 2.20 Ferring's Infertility Product Portfolio, 2005
- Table 2.21 Estimated Global Sales (US$) and Annual Growth (%) of Ferring's Infertility Drugs, 2005-2012
- Table 2.22 Organon's Hormonal Infertility Product Portfolio, 2005
- Table 2.23 Estimated Global Sales (US$) and Annual Growth (%) of Organon's Hormonal Infertility Products, 2005-2012
- Table 2.24 Serono's Hormonal Infertility Product Portfolio, 2005
- Table 2.25 Estimated Global Sales (US$) and Annual Growth (%) of Serono's Hormonal Infertility Products, 2005-2012
- Table 2.26 Drugs in Research and Development for Infertility, 2005
- Table 3.1 Female Oral Contraceptives in Development, 2005
- Table 3.2 Nonoral Female Contraceptives in Development, 2005
- Table 3.3 Male Contraceptives in Development, 2005
- Table 3.4 Drugs in Development for Infertility, 2005
- Table 4.1 Global Drug Market for Hormonal Contraception and Infertility (US$m), 2004-2012
- Table 4.2 Therapy Area Forecasts for Hormonal Contraceptives and Infertility Drugs, 2012 & 2020
List of Figures
- Figure 1.1 Lifestyle Disorder Characteristics Associated with Contraception
- Figure 1.2 Lifestyle Factors Affecting Fertility
- Figure 2.1 Estimated Sales (US$) and Forecasts of Hormonal Contraceptives and Infertility Drug Sectors, 2004-2012
- Figure 2.2 Estimated Global Market Share for Hormonal Contraceptives and Infertility Drug Sectors, 2005 & 2012
- Figure 4.1 Hormonal Contraceptive and Infertility Therapy Area Forecasts, 2005 & 2012 (US$m)
- Figure 4.2 Market Share of Hormonal Contraception and Infertility Therapy Areas, 2005 & 2012
- Figure 4.3 Comparative Analysis of Leading Contraceptives and Infertility Drug Products, 2004-2012 (US$m)
- Figure 4.4 Key Contraception Prospects in the Development Pipeline, 2005
- Figure 4.5 Key Infertility Drug Prospects in the Development Pipeline, 2005